Johnson & Johnson has signed a deal with ViiV Healthcare, the HIV-focused venture majority-owned by GlaxoSmithKline, to spin their two antivirals into a single tablet.
Johnson & Johnson has signed a deal with ViiV Healthcare, the HIV-focused venture majority-owned by GlaxoSmithKline, to spin their two antivirals into a single tablet, potentially sparing patients from some harsh side effects associated with current therapies and challenging Gilead Sciences' dominance in the field.
With the ink still drying on a $365 million deal to in-license rights to a therapeutic cancer vaccine and immunotherapy tech at Aduro BioTech, J&J is back with the news that it is also helping to bankroll the company's research work, jumping into a syndicate which has pledged $55 million to fuel an advanced drug study.
For an idea of what kind of year a drug developer had, take a look at what it paid its head of R&D. Click through our roundup for a look at who ranks where in the biopharma R&D world. Read more >>
In the wake of a lawsuit brought by two California counties against five manufacturers of prescription painkillers, the city of Chicago has filed a suit of its own. Chicago is suing the same five pharma companies--alleging, much like California does, that they overstated the benefits of opioid painkillers while deceiving the public about the risks.
Johnson & Johnson, Bausch + Lomb and rival companies were slapped with a combined $3 million fine by Chinese authorities for price fixing in the country's contact lens and eye-glass market, complicating the companies' growing presence in the country's device sector.
Results are in from a showdown between chronic lymphocytic leukemia drugs Imbruvica, from Johnson & Johnson's Janssen unit, and GlaxoSmithKline's Arzerra. And as it turns out, it wasn't much of a contest.
Having made the big decisions about how their database of clinical trial investigators will work, collaborators Eli Lilly, Merck and Johnson & Johnson are looking to add more members to a roster already swelled by the arrival of Novartis and Pfizer.
Johnson & Johnson's busy deal team in California has nailed down another development pact--this time zeroing in on new technology at a Berkeley biotech that will be used to expand its considerable efforts on prostate cancer R&D.
About a year after launching with the help of Atlas Venture and Johnson & Johnson's Massachusetts biotech incubator, Cambridge's Rodin Therapeutics is setting out with $12.9 million in Series A cash and a plan to apply some cutting-edge science to common central nervous system disorders.